Subscribe
Business

Aveo says FDA refuses to approve cancer drug

By Washington Examiner
Published
Add Washington Examiner on Google

NEW YORK (AP) — Aveo Oncology said Monday that the Food and Drug Administration has refused to approve its cancer drug tivozanib, saying the clinical trial data supporting the drug was not clear.

Aveo, whose formal name is Aveo Pharmaceuticals Inc., is seeking approval for tivozanib as a treatment for advanced renal cell carcinoma, the most common type of kidney cancer.

Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.